Tests nicotinamide riboside in people with smooth muscle dysfunction syndrome
Tests nicotinamide riboside in people with a rare disease affecting smooth muscle function.
Key facts
- Who runs it
- The University of Texas Health Science Center, Houston
- Where
- Houston, United StatesSee the site
- Trial code
- Registry title
- Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 15 people, planned
- Started
- 6 Mar 2024
- Expected to end
- 25 Jul 2027
- Type of study
- Interventional
- Treatments tested
- Nicotinamide riboside (NR)
- Record updated
- 12 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with smooth muscle dysfunction syndrome (SMDS) who have a confirmed ACTA2 gene change at arginine 179. It tests nicotinamide riboside (NR).
- Age
- 1 year and older
- Sex
- All sexes
- Disease stage
- Diagnosed smooth muscle dysfunction syndrome (SMDS).
- Earlier treatment
- Must not have taken niacin or nicotinamide riboside supplements in the prior eight weeks. Must not have had surgery to replace the ascending or root aorta with a graft.
- Biomarker or test result
- Confirmed ACTA2 mutation disrupting arginine 179.
Main reasons for not taking part
- Surgery to replace aneurysmal or dissected ascending and root aortic tissue with a graft
- Other medical conditions that impair the ability to take part
- Known allergy or sensitivity to niacin or nicotinamide riboside
- Niacin or nicotinamide riboside supplement in the prior eight weeks
- Taking part in another intervention trial at the same time
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Individuals diagnosed with SMDS with confirmed ACTA2 mutation disrupting arginine 179
- Parental/guardian permission (informed consent) and, if appropriate, child assent
Who cannot take part
- Individuals who have undergone surgery to replace aneurysmal or dissected ascending and root aortic tissue with a graft
- Prior consumption of niacin or nicotinamide riboside supplement within the prior eight weeks
- Concurrent participation in another intervention trial
- Additional medical conditions that impair the patient's ability to participate in the study
- Known allergy or sensitivity to niacin or nicotinamide riboside
- Failure to provide informed consent
Where in United States
- The University of Texas Health Science Center at HoustonHouston, United StatesContact: Dianna Milewicz, MD, PhDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to determine whether SMDS patients treated with NR at the proposed dose exhibit decreased glucose uptake in the aorta, to determine if NR treatment results in measurable changes of blood NAD+ and NR levels, to determine if aortic measurements are stable after treatment with NR and to evaluate the safety and tolerability of NR in SMDS patients.
The group in the trial
- TreatmentTreatment being tested
Treatment: Nicotinamide riboside (NR)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)
- Plain-language title
- Tests nicotinamide riboside in people with smooth muscle dysfunction syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 12 September 2025